Decoglurant

Decoglurant
Clinical data
Other names	RG1578 and RO4995819
ATC code	none;
Legal status
Legal status	Development terminated;
Identifiers
	IUPAC name 5-({7-(Trifluoromethyl)-5-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl}ethynyl)-2-pyridinamine;
CAS Number	911115-16-7;
PubChem CID	71533696;
ChemSpider	32695160;
UNII	5VX4P0JKC5;
KEGG	D10875;
CompTox Dashboard (EPA)	DTXSID001031872 ;
Chemical and physical data
Formula	C21H11F6N5
Molar mass	447.344 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1=CC(=CC=C1C2=NC3=C(C=NN3C(=C2)C(F)(F)F)C#CC4=CN=C(C=C4)N)C(F)(F)F;
	InChI InChI=1S/C21H11F6N5/c22-20(23,24)15-6-4-13(5-7-15)16-9-17(21(25,26)27)32-19(31-16)14(11-30-32)3-1-12-2-8-18(28)29-10-12/h2,4-11H,(H2,28,29); Key:DMJHZVARRXJSEG-UHFFFAOYSA-N;

Decoglurant (INN; development codes RG1578 and RO4995819) is a negative allosteric modulator of the mGlu₂ and mGlu₃ receptors which was under development by Roche for the adjunctive treatment of major depressive disorder.^[1]^[2] Decoglurant progressed as far as phase II clinical trials^[1]^[2] but was ultimately discontinued from further development due to disappointing efficacy results.^[3]^[4]

References

^ ^a ^b "Roche – Pipeline". 2014. Archived from the original on 2022-10-23. Retrieved 2014-08-01.
^ ^a ^b "Roche Group Development Pipeline" (PDF). 2014. Archived from the original (PDF) on 2014-08-08. Retrieved 2014-08-01.
^ "Roche – Pipeline" (PDF). 2015. Archived from the original (PDF) on 2015-05-01. Retrieved 2015-05-14.
^ Lawrence J (March 2015). "The Secret Life of ketamine". The Pharmaceutical Journal. 294 (7854/5).